Hengsai Biologics

Hengsai Biologics is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on the development of innovative dendritic cell (DC) therapies for the treatment of solid tumors. The company utilizes a proprietary platform to develop personalized neoantigen-loaded DC vaccines, which are designed to activate the patient's immune system to specifically target and eliminate cancer cells. Their lead candidate, HS-IT-101, is currently being evaluated in clinical trials for pancreatic cancer, a high-unmet-need indication. Hengsai's approach combines advanced genomic sequencing with optimized cell manufacturing to produce high-potency immunotherapies. The company is backed by prominent venture capital firms and maintains collaborations with top-tier clinical institutions in China. By focusing on the unique mutational profile of each patient's tumor, Hengsai aims to provide more effective and less toxic alternatives to traditional cancer treatments.